Chronic Lymphocytic Leukemia

Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.

Paolo Ghia, MD, PhD, discusses future research directions and potential roles for first-line, fixed-duration ibrutinib plus venetoclax in CLL.

Carsten Niemann, MD, PhD, discusses long-term follow-up data from the phase 3 GLOW trial evaluating fixed-duration ibrutinib plus venetoclax in CLL.

Francisco J. Hernandez-Ilizaliturri, MD, discusses findings from a study investigating immunologic changes in patients with CLL treated with venetoclax.

Farrukh Awan, MD, delves into CAR T-cell therapy and its impact on the chronic lymphocytic leukemia treatment paradigm.

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.

Paolo Ghia, MD, PhD, discusses OS outcomes with first-line ibrutinib plus venetoclax in patients with CLL vs an age-matched general European population.

Patients with treatment-naive CLL who received the BOVen regimen had an increased likelihood of achieving uMRD levels in peripheral blood and bone marrow.

Supriya Gupta, MD, details pros/cons with different BTK inhibitors and promising combination therapies in CLL, as well as how liso-cel is affecting care.

Duvelisib plus venetoclax was active in relapsed/refractory CLL and Richter syndrome with high-risk, TP53-aberrant disease after BTK inhibition.

A panel of medical experts continues their discussion surrounding an array of treatment options for CLL.

Fixed-duration zanubrutinib/venetoclax elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Nirav N. Shah, MD, MSHP, details how BTK degraders could fill an unmet need in pretreated CLL/SLL and highlights promising data seen with NX-5948.

Dr Niemann provides an overview of the evolving treatment landscape of CLL.

Venetoclax-based treatment was associated with poorer outcomes in CLL previously treated with a BTK inhibitor and naive to chemotherapy.

Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.

Pirtobrutinib improved progression-free survival in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.

John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.

First-line pirtobrutinib plus venetoclax and obinutuzumab generated high uMRD6 remission rates among patients with chronic lymphocytic leukemia.

Sonrotoclax plus zanubrutinib produced responses and was well tolerated in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over SOC chemoimmunotherapy in patients with treatment-naive CLL.

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Meaningful thresholds for interpreting changes in 3 EORTC QLQ-CLL17 domain scores have been identified in a PRO analysis of the TRANSCEND CLL 004 trial.

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

NX-5948 has received PRIME designation from the EMA for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

An NDA for lisaftoclax in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma has been accepted for review.

The FDA has approved revised drug labeling for fludarabine phosphate under Project Renewal.